Chief Executive Officer

Chief Medical Officer

Board Member

Peder M Andersen is a Doctor of Medicine (MD) from Copenhagen University Medical School, graduated in 1981.

His medical training was in surgery (Orthopedic and Abdominal),Anesthesiology/Intensive Care and Internal Medicine from 1981 to 1987 when he joined the Pharmaceutical Industry.

His professional Pharmaceutical experience runs over 30 years and includes:

CEO at Biosergen AS (Invasive Fungal Infections) since 2007 with IPO in Sweden 2021, and since February 2024 consultant CMO, CEO at Forward Pharma 2012-2017, with IPO on New York Nasdaq 2014 raising 235 M USD. Managing director at Forward Pharma Germany 2009 – 2016 developing DMF (psoriasis and MS). Vice President at Astion Pharma 2007-2009 (Psoriasis and Lupus). Medical Director at Novo Nordisk – Nasal Insulin and HGH. International Medical Expert at Sandoz AG, Basel, GM-CSF devl. Medical Monitor Sandoz AS, DK – GM-CSF, Mb Crohn, Psoriasis.

Board Chairman

Chief Scientific Officer

Co-Founder

William Fahl is the inventor of PrC-210 and other compounds that protect cancer patients from the side effects of radiation and chemotherapy.

Bill is Professor of Oncology at the McArdle Laboratory for Cancer Research at the University of Wisconsin-Madison, USA and Member of the University of Wisconsin Carbone Cancer Center.

He graduated in Zoology and Oncology at the University of Wisconsin, USA where he also received his PhD. He has been Associate Professor of Pharmacology at the Northwestern University Medical School in Chicago.

Bill is a highly recognized expert in the field of radiation protection. He is the author of more than 110 scientific publications.

DVM, PhD, DABT, ERT

Toxicology

Harri Jarvelainen has more than 25 years of diverse scientific, managerial and executive experience covering pre-clinical drug development, toxicology and clinical development.

As a biotech entrepreneur and consultant, he has advised more than 50 international biotechnology companies and also held senior drug development positions in pharmaceutical companies such as AstraZeneca.

Harri holds a degree in Veterinary Medicine and PhD from the University of Helsinki. He went to the New York University Medical Center and the Max Planck Institute in Berlin for his post-doctoral training. He became Adjunct Professor of Toxicology at University of Helsinki in 2004.

Harri is Board Certified in Toxicology in the US (DABT) and Europe (ERT).